Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Non-Current Deferred Tax Liability (2017 - 2026)

Bioceres Crop Solutions' Non-Current Deferred Tax Liability history spans 10 years, with the latest figure at $24.3 million for Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to $24.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $24.3 million, a N/A change, with the full-year FY2025 number at $30.1 million, down 13.99% from a year prior.
  • Non-Current Deferred Tax Liability hit $24.3 million in Q1 2026 for Bioceres Crop Solutions, down from $30.1 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for BIOX hit a ceiling of $35.0 million in Q2 2024 and a floor of $1.5 million in Q2 2022.
  • Historically, Non-Current Deferred Tax Liability has averaged $23.9 million across 5 years, with a median of $28.8 million in 2023.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: crashed 94.01% in 2022 and later skyrocketed 1772.12% in 2023.
  • Tracing BIOX's Non-Current Deferred Tax Liability over 5 years: stood at $1.5 million in 2022, then skyrocketed by 1772.12% to $28.8 million in 2023, then grew by 21.52% to $35.0 million in 2024, then decreased by 13.99% to $30.1 million in 2025, then dropped by 19.27% to $24.3 million in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for BIOX at $24.3 million in Q1 2026, $30.1 million in Q2 2025, and $35.0 million in Q2 2024.